MYC and cancer: Pathway analysis in tumors subjected to the two treatments suggested the downregulation of gene sets involved in cellular proliferation represented by E2F targets, G2M checkpoints, and MYC targets, whose high score is typically associated with a proliferative cancer phenotype and aggressiveness [42].